LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article: Development of a pharmacist-led internal medicine outpatient consult service.

    Turgeon, Ricky D / Partovi, Nilu / Dahri, Karen / Kuyper, Laura / Au, Charles

    Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC

    2021  Volume 154, Issue 2, Page(s) 83–86

    Language English
    Publishing date 2021-01-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2200008-2
    ISSN 1913-701X ; 1715-1635
    ISSN (online) 1913-701X
    ISSN 1715-1635
    DOI 10.1177/1715163520985548
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 932: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents.

    Hong, Jenny / Wright, Robert C / Partovi, Nilu / Yoshida, Eric M / Hussaini, Trana

    Journal of clinical and translational hepatology

    2020  Volume 8, Issue 3, Page(s) 322–335

    Abstract: In this review, we examine the pharmacokinetics and clinically relevant drug interactions of the newer generation direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C, specifically sofosbuvir/velpatasvir ( ... ...

    Abstract In this review, we examine the pharmacokinetics and clinically relevant drug interactions of the newer generation direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C, specifically sofosbuvir/velpatasvir (Epclusa
    Language English
    Publishing date 2020-07-30
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 3019822-7
    ISSN 2310-8819 ; 2225-0719
    ISSN (online) 2310-8819
    ISSN 2225-0719
    DOI 10.14218/JCTH.2020.00034
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Early Persistent Progressive Acute Kidney Injury and Graft Failure Post Liver Transplantation.

    Hussaini, Trana / Yoshida, Eric M / Partovi, Nilu / Erb, Siegfried R / Scudamore, Charles / Chung, Stephen / Marquez, Vladimir

    Transplantation direct

    2019  Volume 5, Issue 3, Page(s) e429

    Abstract: Background: Acute kidney injury (AKI) in the setting of liver transplantation is a common and multifaceted complication. Studies in the general population have demonstrated worse prognosis with AKI episodes that persist for a longer duration. Our ... ...

    Abstract Background: Acute kidney injury (AKI) in the setting of liver transplantation is a common and multifaceted complication. Studies in the general population have demonstrated worse prognosis with AKI episodes that persist for a longer duration. Our primary objective was to evaluate the impact of early AKI episodes that are persistent or progressive in nature, on patient outcomes and graft survival.
    Methods: This was a retrospective cohort study including all patients who received a liver transplant between 2011 and 2015 at our center. Moderate to severe AKI episodes (AKIN II or III) were recorded immediately before transplantation and after surgery until hospital discharge. We evaluated the incidence density rate (IDR) of graft failure and the time to graft failure in patients with persistent or progressive AKI (
    Results: Two hundred seventy-nine patients received 301 deceased donor liver allografts. Progressive or persistent AKI was documented in more than half of transplant cases (152/301). The rate of graft loss was 3 times higher in the
    Conclusions: Persistent or progressive AKI after liver transplantation is associated with an increased incidence rate of graft failure and is an independent predictor of decreased graft survival time.
    Language English
    Publishing date 2019-02-20
    Publishing country United States
    Document type Journal Article
    ISSN 2373-8731
    ISSN 2373-8731
    DOI 10.1097/TXD.0000000000000868
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study.

    Stukas, Sophie / Goshua, George / Kinkade, Angus / Grey, Rebecca / Mah, Gregory / Biggs, Catherine M / Jamal, Shahin / Thiara, Sonny / Lau, Tim T Y / Piszczek, Jolanta / Partovi, Nilu / Sweet, David D / Lee, Agnes Y Y / Wellington, Cheryl L / Sekhon, Mypinder S / Chen, Luke Y C

    Lancet Regional Health. Americas

    2022  Volume 11, Page(s) 100228

    Abstract: Background: Interleukin-6 inhibitors reduce mortality in severe COVID-19. British Columbia began using tocilizumab 8 mg/kg (maximum 800 mg) in January 2021 in critically ill patients with COVID-19, but due to drug shortages, decreased dosing to 400 mg ... ...

    Abstract Background: Interleukin-6 inhibitors reduce mortality in severe COVID-19. British Columbia began using tocilizumab 8 mg/kg (maximum 800 mg) in January 2021 in critically ill patients with COVID-19, but due to drug shortages, decreased dosing to 400 mg IV fixed dose in April 2021. The aims of this study were twofold: to compare physiological responses and clinical outcomes of these two strategies, and examine the cost-effectiveness of treating all patients with 400 mg versus half the patients with 8 mg/kg and the other half without tocilizumab.
    Methods: This was a single-centre, before-after cohort study of critically ill COVID-19 patients treated with tocilizumab, and a control cohort treated with dexamethasone only. Physiological responses and clinical outcomes were compared between patients receiving both doses of tocilizumab and those receiving dexamethasone only. We built a decision tree model to examine cost-effectiveness.
    Findings: 152 patients were included; 40 received tocilizumab 8 mg/kg, 59 received 400 mg and 53 received dexamethasone only. Median CRP fell from 103 mg/L to 5.2 mg/L, 96 mg/L to 6.8 mg/L and from 81.3 mg/L to 48 mg/L in the 8 mg/kg, 400 mg tocilizumab, and dexamethasone only groups, respectively. 28-day mortality was 5% (
    Interpretation: Both doses of tocilizumab demonstrated comparable reduction of inflammation with similar 28-day mortality. Without consideration of equity, the net monetary benefits of providing 400 mg tocilizumab to all patients are comparable to 8 mg/kg to half the patients. In the context of ongoing drug shortages, fixed-dose 400 mg tocilizumab may be a practical, feasible and economical option.
    Funding: This work was supported by a gift donation from Hsu & Taylor Family to the VGH Foundation, and the Yale Bernard G. Forget Scholarship.
    Language English
    Publishing date 2022-03-23
    Publishing country England
    Document type Journal Article
    ISSN 2667-193X
    ISSN (online) 2667-193X
    DOI 10.1016/j.lana.2022.100228
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Subcutaneous hepatitis B immune globulin after liver transplantation.

    Yoshida, Eric M / Partovi, Nilu / Greanya, Erica D

    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society

    2012  Volume 18, Issue 8, Page(s) 999; author reply 1000–1

    MeSH term(s) Female ; Hepatitis B/prevention & control ; Humans ; Immunoglobulins/therapeutic use ; Liver Transplantation/psychology ; Male ; Quality of Life ; Surveys and Questionnaires
    Chemical Substances Immunoglobulins
    Language English
    Publishing date 2012-08
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 2006866-9
    ISSN 1527-6473 ; 1527-6465
    ISSN (online) 1527-6473
    ISSN 1527-6465
    DOI 10.1002/lt.23454
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4702: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Impact of early in-hospital medication review by clinical pharmacists on health services utilization.

    Hohl, Corinne M / Partovi, Nilu / Ghement, Isabella / Wickham, Maeve E / McGrail, Kimberlyn / Reddekopp, Lisa N / Sobolev, Boris

    PloS one

    2017  Volume 12, Issue 2, Page(s) e0170495

    Abstract: Background: Adverse drug events are a leading cause of emergency department visits and unplanned admissions, and prolong hospital stays. Medication review interventions aim to identify adverse drug events and optimize medication use. Previous ... ...

    Abstract Background: Adverse drug events are a leading cause of emergency department visits and unplanned admissions, and prolong hospital stays. Medication review interventions aim to identify adverse drug events and optimize medication use. Previous evaluations of in-hospital medication reviews have focused on interventions at discharge, with an unclear effect on health outcomes. We assessed the effect of early in-hospital pharmacist-led medication review on the health outcomes of high-risk patients.
    Methods: We used a quasi-randomized design to evaluate a quality improvement project in three hospitals in British Columbia, Canada. We incorporated a clinical decision rule into emergency department triage pathways, allowing nurses to identify patients at high-risk for adverse drug events. After randomly selecting the first eligible patient for participation, clinical pharmacists systematically allocated subsequent high-risk patients to medication review or usual care. Medication review included obtaining a best possible medication history and reviewing the patient's medications for appropriateness and adverse drug events. The primary outcome was the number of days spent in-hospital over 30 days, and was ascertained using administrative data. We used median and inverse propensity score weighted logistic regression modeling to determine the effect of pharmacist-led medication review on downstream health services use.
    Results: Of 10,807 high-risk patients, 6,416 received early pharmacist-led medication review and 4,391 usual care. Their baseline characteristics were balanced. The median number of hospital days was reduced by 0.48 days (95% confidence intervals [CI] = 0.00 to 0.96; p = 0.058) in the medication review group compared to usual care, representing an 8% reduction in the median length of stay. Among patients under 80 years of age, the median number of hospital days was reduced by 0.60 days (95% CI = 0.06 to 1.17; p = 0.03), representing 11% reduction in the median length of stay. There was no significant effect on emergency department revisits, admissions, readmissions, or mortality.
    Limitations: We were limited by our inability to conduct a randomized controlled trial, but used quasi-random patient allocation methods and propensity score modeling to ensure balance between treatment groups, and administrative data to ensure blinded outcomes ascertainment. We were unable to account for alternate level of care days, and therefore, may have underestimated the treatment effect in frail elderly patients who are likely to remain in hospital while awaiting long-term care.
    Conclusions: Early pharmacist-led medication review was associated with reduced hospital-bed utilization compared to usual care among high-risk patients under 80 years of age, but not among those who were older. The results of our evaluation suggest that medication review by pharmacists in the emergency department may impact the length of hospital stay in select patient populations.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; British Columbia ; Drug Therapy/statistics & numerical data ; Drug-Related Side Effects and Adverse Reactions/diagnosis ; Female ; Hospitalization ; Hospitals ; Humans ; Length of Stay/statistics & numerical data ; Male ; Middle Aged ; Pharmacists ; Pharmacy Service, Hospital/methods ; Pilot Projects ; Prospective Studies ; Reproducibility of Results ; Risk Assessment/methods ; Risk Assessment/statistics & numerical data ; Risk Factors
    Language English
    Publishing date 2017-02-13
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0170495
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Successful lung transplantation in an HIV seropositive patient with desquamative interstitial pneumonia: a case report.

    Ong, Shaun / Levy, Robert D / Yee, John / Partovi, Nilu / Churg, Andrew / Roméo, Philippe / Chalaoui, Jean / Nador, Roland / Wright, Alissa / Manganas, Hélène / Ryerson, Christopher J

    BMC pulmonary medicine

    2018  Volume 18, Issue 1, Page(s) 162

    Abstract: Background: Until recently, lung transplantation was not considered in patients with human immunodeficiency virus (HIV). HIV seropositive patients with suppressed viral loads can now expect long-term survival with the advent of highly active ... ...

    Abstract Background: Until recently, lung transplantation was not considered in patients with human immunodeficiency virus (HIV). HIV seropositive patients with suppressed viral loads can now expect long-term survival with the advent of highly active antiretroviral therapies (HAART); however, HIV remains a relative contraindication to lung transplantation. We describe, to our knowledge, the first HIV seropositive lung transplant recipient in Canada. We also review the literature of previously reported cases of solid-organ transplantation in patients with HIV with a focus on immunosuppression considerations.
    Case presentation: A 48-year old man received a bilateral lung transplant for a diagnosis of desquamative interstitial pneumonia (DIP) attributed to cigarette and cannabis smoking. His control of HIV infection pre-transplant was excellent on HAART, and he had no other contraindications to lung transplantation. The patient underwent bilateral lung transplantation using basiliximab, methylprednisolone, and mycophenolate mofetil (MMF) as induction immunosuppression. He was maintained on MMF, prednisone, and tacrolimus thereafter, and restarted his HAART regimen immediately post-operatively. His post-transplant course was complicated by Grade A1 minimal acute cellular rejection, as well as an enterovirus/rhinovirus graft infection. Despite these complications, his functional status and control of HIV infection remain excellent 24 months post-transplant.
    Conclusions: Our patient is one of only several HIV seropositive lung transplant recipients reported globally. With growing acceptance of transplantation in this population, there is a need for clarification of prognosis post-transplantation, as well as optimal immunosuppression regimens for these patients. This case report adds to the recent literature that suggests HIV seropositivity should not be considered a contraindication to lung transplantation, and that post-transplant patients with HIV can be managed safely with basiliximab, tacrolimus, MMF and prednisone.
    MeSH term(s) Antiretroviral Therapy, Highly Active ; Canada ; Genetic Diseases, Inborn/drug therapy ; Genetic Diseases, Inborn/surgery ; Graft Rejection ; HIV Seropositivity/complications ; HIV Seropositivity/drug therapy ; Humans ; Immunosuppressive Agents/therapeutic use ; Lung Diseases, Interstitial/drug therapy ; Lung Diseases, Interstitial/surgery ; Lung Transplantation ; Male ; Middle Aged ; Tomography, X-Ray Computed
    Chemical Substances Immunosuppressive Agents
    Language English
    Publishing date 2018-10-16
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2059871-3
    ISSN 1471-2466 ; 1471-2466
    ISSN (online) 1471-2466
    ISSN 1471-2466
    DOI 10.1186/s12890-018-0727-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence.

    Singham, Janakie / Greanya, Erica D / Lau, Kirby / Erb, Siegfried R / Partovi, Nilu / Yoshida, Eric M

    Annals of hepatology

    2010  Volume 9, Issue 2, Page(s) 166–171

    Abstract: Background: Patients who receive liver transplantation for chronic hepatitis B infection require long-term combination therapy with hepatitis B immunoglobulin (HBIG) and oral antiviral medication to prophylax against graft re-infection. This study ... ...

    Abstract Background: Patients who receive liver transplantation for chronic hepatitis B infection require long-term combination therapy with hepatitis B immunoglobulin (HBIG) and oral antiviral medication to prophylax against graft re-infection. This study examines the efficacy and patient preference of subcutaneous (SC) administration of HBIG in maintaining anti HBs titres > 100 IU/L.
    Materials and methods: 12 patients who were stable while receiving our standard IM HBIG protocol received an alternate formulation by SC injection, consisting of 10 mL (3120 IU) HBIG as 4 x 2.5 mL SC injections. SC injection were repeated as soon as titres reached 100-150 IU/mL during the 3 month study period. A questionnaire was administered upon study entry and exit to subjectively assess patient preference.
    Results: Anti- HBs Cmax after first injection was 441.6 IU/L +/- 81.5, and Tmax was 7.1 +/- 3.2 days. SC injections were required every 56 days, which compared well to the frequency of required IM injections prior to study enrollment of 45 days. The patients mean ratings of pain on a 0-10 scale were 5 for the IM route and 1.6 for the SC route. All patients preferred the SC injections to the IM.
    Conclusion: SC administration of HBIG can effectively maintain anti HBs levels above the requisite 100 IU/L while substantially decreasing patient discomfort and improving patient satisfaction, and therefore becomes a very attractive alternative to IM HBIG injections. Further studies and wider use of SC HBIG based on this study may alter the standard practice of transplantation centers
    MeSH term(s) Adult ; Aged ; Antiviral Agents/therapeutic use ; British Columbia ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Hepatitis B Antibodies/blood ; Hepatitis B Vaccines/administration & dosage ; Hepatitis B, Chronic/complications ; Hepatitis B, Chronic/prevention & control ; Hepatitis B, Chronic/surgery ; Humans ; Immunoglobulins/administration & dosage ; Injections, Intramuscular ; Injections, Subcutaneous ; Liver Transplantation/adverse effects ; Male ; Middle Aged ; Patient Preference ; Pilot Projects ; Prospective Studies ; Secondary Prevention ; Surveys and Questionnaires ; Time Factors ; Treatment Outcome
    Chemical Substances Antiviral Agents ; Hepatitis B Antibodies ; Hepatitis B Vaccines ; Immunoglobulins ; hepatitis B hyperimmune globulin (XII270YC6M)
    Language English
    Publishing date 2010-04
    Publishing country Mexico
    Document type Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2188733-0
    ISSN 1665-2681
    ISSN 1665-2681
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6221: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top